Page results
-
Among the many cancer clinical trials opening each year at UCLH, this year will see a focus on trials of personalised cancer treatments based on precision immunotherapies.
-
The NHS has become the first healthcare system in the world to provide a new blood group genotyping test which is set to transform care for patients living with sickle cell disorder and thalassaemia.
-
RESPOND – Information for healthcare professionals and services working with asylum seekers
-
UCLH is continuing to scale up the number of services that offer Advice & Guidance, as well as identifying various improvements within the existing Advice & Guidance service. Over the last few months, UCLH has introduced 5 new specialties to the service, with additional specialties due to go live shortly.
-
Information about preparing for and undergoing surgery at University College London Hospitals NHS Foundation Trust.
-
Researchers at UCLH have begun a study which could set the foundations for how booster COVID-19 vaccinations are delivered in the future.
-
UCLH has recruited the first participant for a new UK based study for Parkinson’s Disease (PD). The ASPro-PD study is testing whether treatment with a drug called ambroxol is associated with an improvement in motor and non-motor function compared with placebo.
-
This page explains what patient-initiated follow-up (PIFU) involves after your treatment for endometrial (uterine or womb) cancer.
-
This page has been written by the team in the mitochondrial clinic for patients who are seen at the National Hospital for Neurology and Neurosurgery, who have a diagnosis of mitochondrial disease.
-
Fiona Farrell works at the Sir William Gowers Unit, a specialist treatment centre for epilepsy and related disorders.
File results
-
FOI/2024/0326 - Treatment of Haemophilia B and Von Willebrand disease
-
FOI/2024/0327 - Treatment of non-UK nationals
-
FOI/2024/0329 - Metastatic renal cell carcinoma patients/ classification
-
FOI/2024/0464 - Theatre sessions/ productivity
-
FOI/2024/0467 - Drug Patient Level Contract Monitoring (DrPLCM) and SACT Cancer reports
-
FOI/2024/0333 - Elective treatment wait over 65 weeks
-
FOI/2024/0337 - IVF clinical unit/ embryology laboratory
-
FOI/2024/0338 - Ophthalmology outpatient activity 2022, 2023 and 2024
-
FOI/2024/0339 - PACS, VNA, RIS, digital pathology and cardiology PACS systems
-
FOI/2024/0341 - Robotic Process Automation (RPA)/ Intelligent Automation (IA) technology at Trust